The Nup107 antibody is a crucial tool for studying the nuclear pore complex (NPC), a large protein assembly embedded in the nuclear envelope that regulates nucleocytoplasmic transport. Nup107 is a core component of the NPC, forming part of the conserved Nup107-160 subcomplex, which is essential for NPC structure, assembly, and function. This subcomplex plays roles in mitosis, post-mitotic nuclear envelope reformation, and maintaining transport selectivity. Dysregulation of Nup107 is linked to diseases, including cancers and developmental disorders.
Antibodies targeting Nup107 enable researchers to investigate its expression, localization, and interactions via techniques like Western blotting, immunofluorescence, and immunoprecipitation. They are particularly valuable in studies exploring cell cycle-dependent NPC dynamics, nuclear transport defects, or pathological conditions associated with NPC dysfunction. For example, Nup107 antibodies have been used to examine mitotic errors in cancer cells or viral infection mechanisms that hijack NPC components.
Most Nup107 antibodies are raised against conserved epitopes, often in model organisms like humans or mice, and validated for specificity through knockdown/knockout controls. Commercial antibodies typically specify host species (e.g., rabbit, mouse), clonality (monoclonal/polyclonal), and recommended applications. Researchers prioritize antibodies validated in their specific experimental systems (e.g., frozen tissues, cultured cells) to ensure reliability. Overall, Nup107 antibodies remain indispensable for dissecting NPC biology and its implications in health and disease.